Analysis of the fine B cell specificity during the chronic/relapsing course of a multiple sclerosis-like disease in Lewis rats injected with the encephalitogenic myelin oligodendrocyte glycoprotein peptide 35-55 - PubMed (original) (raw)
. 1996 Jul 15;157(2):919-26.
Affiliations
- PMID: 8752946
Analysis of the fine B cell specificity during the chronic/relapsing course of a multiple sclerosis-like disease in Lewis rats injected with the encephalitogenic myelin oligodendrocyte glycoprotein peptide 35-55
M Ichikawa et al. J Immunol. 1996.
Abstract
We have recently shown that a single injection of myelin oligodendrocyte glycoprotein (MOG), or the MOG35-55 peptide, produces a relapsing-remitting neurologic disease with extensive plaque-like demyelination. Given the features that this new autoimmune demyelinating model has in common with the clinicopathologic manifestations of multiple sclerosis, we have examined the Ab reactivity to native MOG and MOG35-55 peptide during the course of the disease in Lewis rats. Following immunization with MOG35-55, varied clinical symptoms were observed; these included hind and foreleg paralysis and various degrees of balance impairment. Disease progression also varied: 3 out of 21 animals had a single mild disease episode; 4 out of 21 had a mild relapsing-remitting disease; and 14 out of 21 had severe relapsing-remitting disease. Ab reactivity to MOG35-55 and native MOG was first detected in all rats 4 wk postimmunization and persisted throughout the 12 wk of observation. The Ab response was highly restricted with no reactivity to other peptides encompassing different extracellular segments of MOG. Fine epitope mapping showed that Ab from serum and cerebrospinal fluid of injected rats reacted strongly to MOG37-46 and to a lesser extent to MOG43-50. Although significant levels of anti-MOG Abs appeared necessary for the development of demyelinating lesions, their presence in blood and cerebrospinal fluid alone was not sufficient to produce severe clinical symptoms. These results demonstrate that the MOG35-55 peptide is highly encephalitogenic and can induce strong T and B cell responses. It is probably the complex interaction between these T and B cells that determines the severity of disease in individual rats.
Similar articles
- Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis.
Bernard CC, Johns TG, Slavin A, Ichikawa M, Ewing C, Liu J, Bettadapura J. Bernard CC, et al. J Mol Med (Berl). 1997 Feb;75(2):77-88. doi: 10.1007/s001090050092. J Mol Med (Berl). 1997. PMID: 9083925 Review. - IgG subclass switching is associated with the severity of experimental autoimmune encephalomyelitis induced with myelin oligodendrocyte glycoprotein peptide in NOD mice.
Ichikawa M, Koh CS, Inaba Y, Seki C, Inoue A, Itoh M, Ishihara Y, Bernard CC, Komiyama A. Ichikawa M, et al. Cell Immunol. 1999 Feb 1;191(2):97-104. doi: 10.1006/cimm.1998.1414. Cell Immunol. 1999. PMID: 9973531 - T-cell responses to myelin antigens in multiple sclerosis; relevance of the predominant autoimmune reactivity to myelin oligodendrocyte glycoprotein.
de Rosbo NK, Ben-Nun A. de Rosbo NK, et al. J Autoimmun. 1998 Aug;11(4):287-99. doi: 10.1006/jaut.1998.0202. J Autoimmun. 1998. PMID: 9776706 Review.
Cited by
- The Translatability of Multiple Sclerosis Animal Models for Biomarkers Discovery and Their Clinical Use.
Birmpili D, Charmarke Askar I, Bigaut K, Bagnard D. Birmpili D, et al. Int J Mol Sci. 2022 Sep 29;23(19):11532. doi: 10.3390/ijms231911532. Int J Mol Sci. 2022. PMID: 36232832 Free PMC article. Review. - Rational design and synthesis of altered peptide ligands based on human myelin oligodendrocyte glycoprotein 35-55 epitope: inhibition of chronic experimental autoimmune encephalomyelitis in mice.
Tselios T, Aggelidakis M, Tapeinou A, Tseveleki V, Kanistras I, Gatos D, Matsoukas J. Tselios T, et al. Molecules. 2014 Nov 4;19(11):17968-84. doi: 10.3390/molecules191117968. Molecules. 2014. PMID: 25375337 Free PMC article. - Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination.
von Büdingen HC, Tanuma N, Villoslada P, Ouallet JC, Hauser SL, Genain CP. von Büdingen HC, et al. J Clin Immunol. 2001 May;21(3):155-70. doi: 10.1023/a:1011031014433. J Clin Immunol. 2001. PMID: 11403222 Review. - Structural insights into the antigenicity of myelin oligodendrocyte glycoprotein.
Breithaupt C, Schubart A, Zander H, Skerra A, Huber R, Linington C, Jacob U. Breithaupt C, et al. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9446-51. doi: 10.1073/pnas.1133443100. Epub 2003 Jul 21. Proc Natl Acad Sci U S A. 2003. PMID: 12874380 Free PMC article. - Characterization of Asparagine Deamidation in Immunodominant Myelin Oligodendrocyte Glycoprotein Peptide Potential Immunotherapy for the Treatment of Multiple Sclerosis.
Androutsou ME, Nteli A, Gkika A, Avloniti M, Dagkonaki A, Probert L, Tselios T, Golič Grdadolnik S. Androutsou ME, et al. Int J Mol Sci. 2020 Oct 13;21(20):7566. doi: 10.3390/ijms21207566. Int J Mol Sci. 2020. PMID: 33066323 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Molecular Biology Databases